Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Genetic Disease

Search Medical Condition
Please enter condition
Please choose location from dropdown

Hemophilia Clinical Trials

A listing of Hemophilia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (104) clinical trials

To Investigate Safety and Efficacy of NovoEight (rFVIII) During Long-term Treatment of Haemophilia A in Japan

This study is conducted in Asia. The aim of this study is to evaluate the safety and efficacy of NovoEight (recombinant factor VIII) in patients with haemophilia A in Japan in the setting of routine clinical practice.

Phase N/A

Personalized Prophylactic Treatment With Advate in Severe or Moderate Haemophilia A Patients

Research Question: Is standard prophylaxis effective for all hemophilia A patient? Which are the causes for poor clinical response in some patients on prophylactic treatment? Can differences in PK impact the clinical outcome and effectiveness of prophylaxis? For a given group of poor controlled patients in standard prophylaxis, may personalized ...

Phase N/A

Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea

Primary: To characterize the safety of RIXUBIS when used under normal clinical care in South Korea. Secondary: To describe hemostatic effectiveness in subjects receiving RIXUBIS under normal clinical care in South Korea.

Phase N/A

Evaluate Efficacy and Safety of Recombinant Factor VIII rFVIII Treatment of Severe or Moderately Severe Hemophilia A

Efficacy, Safety and Pharmacokinetics Study of a rFVIII in Chinese subjects with Hemophilia A.To assess efficacy and safety of rFVIII administered as treatment and as on-demand therapy in adult and adolescent (12-65 years) patients with severe or moderately severe Hemophilia A. To determine the pharmacokinetic (PK) parameters of rFVIII.

Phase

Comparison of Ideal vs. Actual Weight Base Factor Dosing

This is a randomized, prospective, multicenter, open-label, crossover study to examine whether or not the current recommended factor dosing strategy, i.e., dosing by actual body weight in overweight and obese patients, may deliver more clotting factor than necessary to cause bleeding to stop in participants with Hemophilia A who use ...

Phase N/A

Prospective Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

The study addresses the safety, utilisation and effectiveness of Obizur in the treatment of bleeding episodes in real-life clinical practice in Europe.

Phase N/A

A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children

In the past, due to economic and medical resource constraints, the hemophilia comprehensive care in China was suboptimal. The BCH data of both retrospective and prospective studies reveals that for 4-6y and 6-9y patients with severe hemophilia respectively: 45% and 82% of the patients have suffered from joint bleeding, with ...

Phase

Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors

Background The treatment of haemophilia A and B has been revolutionized by the use of factor concentrate, both as prophylaxis and to treat bleeding episodes (on-demand treatment). However, despite its advantages, repeated treatment with factor concentrate can lead to development of inhibitors (antibodies) towards the coagulation factor in the concentrate. ...

Phase N/A

Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies

Life expectancy of haemophilia patients (specially severe) has dramatically increase in the last decades, which lead to the apparition of aging diseases such as cardiovascular disease, with the potential bleeding risk of antiplatelet therapies and anticoagulants. The primary endpoint of the study is to evaluate this bleeding risk in haemophilia ...

Phase N/A

DDAVP vs. Exercise in Patients With Mild Hemophilia A

Persons with mild hemophilia A (MHA) (defined as having a FVIII level of >5% to 40%) bleed infrequently but can in the setting of trauma which can often is in the context of participating in sports/exercise. FVIII levels temporarily rise with stress, exercise and with DDAVP (1-desamino-8-D-arginine vasopressin, desmopressin). In ...

Phase